Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TMJ premarket applications based on historically controlled studies urged by TMJ Implants, Inc..

This article was originally published in The Gray Sheet

Executive Summary

USE OF NON-RANDOMIZED, HISTORICALLY CONTROLLED STUDIES IN TMJ PMA submissions is urged by temporomandibular joint implant manufacturer TMJ Implants, Inc. in recent comments to FDA. Responding to FDA's July proposed call for premarket approval applications for partial and total TMJ prostheses, TMJ Implants notes that the preamendments devices have been marketed for over 30 years and "over this time" have become "an acceptable treatment regimen." Therefore, the firm reasons, a randomized trial with a concurrent control is not feasible since it would be impossible "to ask a physician to randomize a patient to [an alternative] treatment regimen that over time has shown to not be the treatment of choice in treating TMJ disorders."



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts